Results 41 to 50 of about 11,689 (208)

Neutralizing Activity against BQ.1.1, BN.1, and XBB.1 in Bivalent COVID-19 Vaccine Recipients: Comparison by the Types of Prior Infection and Vaccine Formulations

Vaccines, 2023
Bivalent COVID-19 vaccines that contain BA.1 or BA.4/BA.5 have been introduced worldwide in response to pandemic waves of Omicron subvariants. This prospective cohort study was aimed to compare neutralizing antibodies (Nabs) against Omicron subvariants ...
Hak-Jun Hyun, Min-Joo Choi, Eliel Nham, Hye Seong, Jin-Gu Yoon, Ji-Yun Noh, Hee-Jin Cheong, Woo-Joo Kim, Sun-Kyung Yoon, Se-Jin Park, Won-Seok Gwak, June-Woo Lee, Byoung-Guk Kim, Joon-Young Song   +13 more
doaj   +1 more source

Reactogenicity to COVID-19 vaccination in the United States of America

Clinical and Experimental Vaccine Research, 2022
In the United States, Pfizer-BioNTech, Moderna, and Janssen's coronavirus disease 2019 (COVID-19) vaccines have been granted Emergency Use Authorization (EUA) with the Pfizer-BioNTech vaccine presently approved by the US Food and Drug Administration. The purpose of this study is to analyze passive surveillance data on COVID-19 vaccine adverse reaction ...
Adekunle Sanyaolu, Aleksandra Marinkovic, Stephanie Prakash, Priyank Desai, Nafees Haider, Abu Fahad Abbasi, Nasima Mehraban, Isha Jain, Amarachi Ekeh, Omar Shazley, Chuku Okorie, Verner N. Orish   +11 more
openaire   +2 more sources

Immunogenicity and reactogenicity of yellow fever vaccine in people with HIV

AIDS, 2023
Objective: To evaluate immunogenicity and reactogenicity of yellow fever (YF) vaccine in people with HIV (PWH) compared to HIV-uninfected controls. Design: In this longitudinal interventional trial (NCT03132311), PWH with CD4+ cell count ≥200 cells/μl and controls, aged 18–59 ...
Motta, Edwiges, Camacho, Luiz Antonio B., Cunha, Marcelo, de Filippis, Ana Maria Bispo, Lima, Sheila M.B., Costa, Marcellus, Pedro, Luciana, Cardoso, Sandra W., Cortes, Fernanda Heloise, Giacoia-Gripp, Carmem B.W., Morata, Michelle, Nazer, Sandro, Moreira, Ronaldo Ismério, de Oliveira Souza, Marta Cristina, Mendes, Ygara S., de Souza Azevedo, Adriana, dos Santos Alvez, Nathalia, Grinsztejn, Beatriz, Coelho, Lara E.   +18 more
openaire   +2 more sources

Comparative Reactogenicity of Enhanced Influenza Vaccines in Older Adults

The Journal of Infectious Diseases, 2020
Abstract Background We analyzed data from a randomized controlled trial on the reactogenicity of 3 enhanced influenza vaccines compared with standard-dose (SD) inactivated influenza vaccine. Methods We enrolled community-dwelling ...
Benjamin J, Cowling, Mark G, Thompson, Tiffany W Y, Ng, Vicky J, Fang, Ranawaka A P M, Perera, Nancy H L, Leung, Yuyun, Chen, Hau Chi, So, Dennis K M, Ip, A Danielle, Iuliano   +9 more
openaire   +2 more sources

COMBINED VACCINES IN PEDIATRIC PRACTICE: WHEN THE PERTUSSIS VACCINE IS FUN!

Педиатрическая фармакология, 2012
Today the tendency towards reducing the invasive techniques in pediatric patients is of current importance. This also applies to vaccination. Creating a modern multi-vaccine reduces the number of painful injections to infants, because most of the ...
V. K. Tatochenko
doaj   +1 more source

Natural killer cells and BNT162b2 mRNA vaccine reactogenicity and durability

Frontiers in Immunology, 2023
IntroductionNatural killer (NK) cells can both amplify and regulate immune responses to vaccination. Studies in humans and animals have observed NK cell activation within days after mRNA vaccination.
Elizabeth K. Graydon, Elizabeth K. Graydon, Tonia L. Conner, Kim Dunham, Cara Olsen, Emilie Goguet, Emilie Goguet, Si’Ana A. Coggins, Si’Ana A. Coggins, Marana Rekedal, Marana Rekedal, Emily Samuels, Emily Samuels, Belinda Jackson-Thompson, Belinda Jackson-Thompson, Matthew Moser, Matthew Moser, Alyssa Lindrose, Alyssa Lindrose, Monique Hollis-Perry, Gregory Wang, Gregory Wang, Santina Maiolatesi, Santina Maiolatesi, Yolanda Alcorta, Yolanda Alcorta, Anatalio Reyes, Anatalio Reyes, Mimi Wong, Mimi Wong, Kathy Ramsey, Kathy Ramsey, Julian Davies, Julian Davies, Edward Parmelee, Edward Parmelee, Orlando Ortega, Orlando Ortega, Mimi Sanchez, Mimi Sanchez, Sydney Moller, Jon Inglefield, David Tribble, Timothy Burgess, Robert O’Connell, Allison M. W. Malloy, Simon Pollett, Simon Pollett, Christopher C. Broder, Eric D. Laing, Stephen K. Anderson, Edward Mitre   +51 more
doaj   +1 more source

Guinea pig reactogenicity model.

, 2018
Guinea pig reactogenicity model.
Richard A. Bowen (221292), Laurie A. Baeten (5851721), Brendan K. Podell (129570), Anja Garritsen (386435), Ann E. Sluder (5851724), Mark C. Poznansky (353701)   +5 more
core   +1 more source

Pneumococcal conjugate 7-valent vacciPNEUMOCOCCAL CONJUGATE 7-VALENT VACCINE IN CHILDREN. REGIONAL EXPERIENCEne in children. Regional experience

Педиатрическая фармакология, 2012
Paper is devoted to one of the most actual problems of early childhood — a pneumococcal infection. The unique preventive way is vaccination. The authors have demonstrated their own experience with pneumococcal conjugate 7-valent vaccine in 196 children 1–
N. L. Chernaya, O. B. Dadayeva, V. M. Ganuzin, G. S. Ganuzina, S. E. Batorshina, I. V. Ivanova   +5 more
doaj   +1 more source

MPL Adjuvant Contains Competitive Antagonists of Human TLR4

Frontiers in Immunology, 2020
Monophosphoryl lipid A (MPL®) is the first non-alum vaccine adjuvant to achieve widespread clinical and market acceptance, a remarkable achievement given that it is manufactured from a Salmonella enterica endotoxin.
Yi-Qi Wang, Hélène Bazin-Lee, Jay T. Evans, Carolyn R. Casella, Thomas C. Mitchell   +4 more
doaj   +1 more source

Dangers of mRNA vaccines

Industrial Psychiatry Journal, 2021
“Necessity is the mother of invention:” An adage was brought to life with the emergence of the mRNA vaccine against the backdrop of the foreboding and mercurial COVID-19 pandemic.
Tahoora Ali, Swaleha Mujawar, A V Sowmya, Daniel Saldanha, Suprakash Chaudhury   +4 more
doaj   +1 more source